120 related articles for article (PubMed ID: 28620348)
1. The Utility of FDG-PET/CT in Clinically Suspected Paraneoplastic Neurological Syndrome: A Literature Review and Retrospective Case Series.
Maskery MP; Hill J; Cain JR; Emsley HCA
Front Neurol; 2017; 8():238. PubMed ID: 28620348
[TBL] [Abstract][Full Text] [Related]
2. Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging.
Opalińska M; Sowa-Staszczak A; Wężyk K; Jagiełła J; Słowik A; Hubalewska-Dydejczyk A
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329862
[TBL] [Abstract][Full Text] [Related]
3.
Harlos C; Metser U; Poon R; MacCrostie P; Mason W
Curr Oncol; 2019 Aug; 26(4):e458-e465. PubMed ID: 31548813
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
[TBL] [Abstract][Full Text] [Related]
5. Whole-Body
Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
[TBL] [Abstract][Full Text] [Related]
6. Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.
Pena Pardo FJ; García Vicente AM; Amo-Salas M; López-Fidalgo JF; Garrido Robles JA; de Ayala Fernández JÁ; Del Saz Saucedo P; Muñoz Pasadas M; Soriano Castrejón A
Clin Transl Oncol; 2017 Jan; 19(1):111-118. PubMed ID: 27139696
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients.
Kristensen SB; Hess S; Petersen H; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2056-63. PubMed ID: 26194717
[TBL] [Abstract][Full Text] [Related]
8. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
11. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
[TBL] [Abstract][Full Text] [Related]
12. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
[TBL] [Abstract][Full Text] [Related]
13. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit.
Hadjivassiliou M; Alder SJ; Van Beek EJ; Hanney MB; Lorenz E; Rao DG; Sharrack B; Tindale WB
Acta Neurol Scand; 2009 Mar; 119(3):186-93. PubMed ID: 18855873
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre.
Vaidyanathan S; Pennington C; Ng CY; Poon FW; Han S
Nucl Med Commun; 2012 Aug; 33(8):872-80. PubMed ID: 22669052
[TBL] [Abstract][Full Text] [Related]
15.
García Vicente AM; Delgado-Bolton RC; Amo-Salas M; López-Fidalgo J; Caresia Aróztegui AP; García Garzón JR; Orcajo Rincón J; García Velloso MJ; de Arcocha Torres M; Alvárez Ruíz S;
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1575-1587. PubMed ID: 28550611
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
17.
Bresler R; Schroeder HW; Chow DZ; Lim R
World J Nucl Med; 2020; 19(2):124-130. PubMed ID: 32939199
[TBL] [Abstract][Full Text] [Related]
18. F-18 FDG PET/CT for detection of malignant involvement of peripheral nerves: case series and literature review.
Bronstein Y; Tummala S; Rohren E
Clin Nucl Med; 2011 Feb; 36(2):96-100. PubMed ID: 21220969
[TBL] [Abstract][Full Text] [Related]
19. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
